Skip to content

Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients With Antiphospholipid Syndrome.

Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03384485
Enrollment
100
Registered
2017-12-27
Start date
2018-02-01
Completion date
2018-10-01
Last updated
2017-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antiphospholipid Syndrome

Brief summary

Fabry disease, an X-linked disorder of glycosphingolipids that is caused by mutations of the GLA gene that codes for α-galactosidase A, leads to dysfunction of many cell types and includes a systemic vasculopathy. As a result, patients have a markedly increased risk of developing ischemic stroke, small-fiber peripheral neuropathy, cardiac dysfunction and chronic kidney disease. Because this disease is a rare disease most of the time it is misdiagnosed, so in this study we will check out the Prevalence of lysosomal hydrolase alpha-glagtosidase deficiency ( Fabry disease) in patients with Antiphospholipid Syndrome.

Detailed description

the investigators would like to assess the prevalence of Fabry in men and women aged 18-100 who were diagnosed with antiphospholipid syndrome in our departmental clinic in 2000-2017 It is very important to diagnose Fabri that then the treatment of patients can vary dramatically. The study will include 100 adult patients (18-100) men and women. Testing for the Fabri test in men is an enzyme test and will be performed subject to their consent to sign informed consent. In the women, an enzyme test will be carried out, and the plasma Lys-3-3 plasma storage, as recommended in the recently published diagnostic algorithms, is examined. If diagnosed, a patient will be referred to a genetic institute for further genetic counseling

Interventions

DIAGNOSTIC_TESTantiphospholipid syndrome

blood test for enzyme test,plasma and Lys-3-3 plasma

Sponsors

Meir Medical Center
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

* Clinical diagnosis of Antiphospholipid syndrome. * able to read and sign inform concent

Exclusion criteria

• Fabry disease.

Design outcomes

Primary

MeasureTime frameDescription
Lys-3-3 plasmaan average of 1 yearblood test to find the enzyme for Fabry's disease

Countries

Israel

Contacts

Primary ContactHitam Hagog
Hitam.hagog@clalit.org.il972-09-7472626
Backup ContactYael Eizikovits
yael.eizikovits@clalit.org.il972-09-7471936

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026